Improvement of subjective well-being and enduring symptomatic remission, A 5-year follow-up of first episode schizophrenia

Pharmacopsychiatry

Volumn 41, Issue 4, 2008, Pages 125-128

  de Haan, L ^a,b   van Nimwegen, L ^a   van Amelsvoort, T ^a   Dingemans, P ^a   Linszen, D ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DELUSIONAL DISORDER; DISEASE SEVERITY; EARLY INTERVENTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLEPTICS SCALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGICAL WELL BEING; PSYCHOSIS; RATING SCALE; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; VALIDITY;

ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; REMISSION, SPONTANEOUS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 49249128798     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1076729     Document Type: Article

References (13)

1. Andreasen NC, Carpenter Jr WT, Kane JM et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441-449
2. Haan L De, Weisfelt M, Dingemans PM et al. Psychometric properties of the subjective well-being under neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology 2002; 162: 24-28
3. Haan L de, Amelsvoort T van, Dingemans P, Linszen D. Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up. Pharmacopsychiatry 2007; 40: 264-268
4. Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics. Pharmacopsychiatry 2006; 39: 47-51
5. Karow A, Czekalla J, Dittmann RW, Schacht A, Wagner T, Lambert M, Schimmelmann B, Naber D. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry 2007; 68: 75-80
6. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
7. Lambert M, Schimmelmann BG, Karow A, Naber D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance. Pharmacopsychiatry 2003; 36: S181-190
8. Lambert M, Schimmelmann BG, Naber D et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006; 67: 1690-1697
9. Lambert M, Eich FX Schacht M, Naber D, Linden M, Schimmelmann BG. Remission of severely impaired subjective well-being in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatrica Scand 2007: 115: 106-113
10. Leucht S, Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 2006; 39: 161-170
11. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995; 10: 133-138
12. Os J Van, Drukker M, Campo J. et al Validation of remission criteria for schizophrenia. Am J Psychiatry 2006; 163: 2000-2002
13. Wehmeier P, Kluge M, Schacht A, Helsberg K, Schreiber W, Lambert M. Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. J Psychiatric Res 2007, in press